Esmoz-D 40 Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed for the management of gastrointestinal disorders associated with acid reflux and delayed gastric emptying. Esomeprazole, a proton pump inhibitor, effectively suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby providing symptomatic relief from conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by accelerating gastric emptying and improving esophageal sphincter tone, which aids in reducing symptoms like nausea, vomiting, bloating, and early satiety. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, enhancing patient compliance and efficacy. Esmoz-D 40 is indicated for patients requiring both acid suppression and prokinetic therapy, particularly when delayed gastric emptying complicates acid-related disorders. It should be used under medical supervision, with caution in patients with cardiac conditions due to Domperidone’s potential to prolong the QT interval. Contraindications include hypersensitivity to either component and concurrent use with medications known to prolong QT interval. Regular monitoring and adherence to prescribed dosage are recommended to optimize therapeutic outcomes and minimize adverse effects.